Guilin Pharmaceutical

Product category
  • Sulfadoxine-pyrimethamine + amodiaquine in child-friendly dispersible formulation

  • Chemoprevention

Therapeutic indication
  • Seasonal Malaria Chemoprevention for children 3 to 59 months in eligible region

  • Once daily for 3 days (amodiaquine) and one day (sulfadoxine-pyrimethamine), administered in monthly cycles for 4 months 

  • 75% reduction in malaria episodes in pivotal trials

Key features
  • Recommended by WHO for the prevention of malaria in children in areas of high seasonal malaria transmission

  • Average cost to protect a child: US$3.40 per year (drug costs + delivery)

  • The sole prequalified supplier

  • Drug distribution to healthy subjects mainly via door-to-door campaigns

  • >350 million treatments distributed since launch in 2014 (see map)

  • First taste-masked dispersible SPAQ formulation prequalified by WHO

Next milestone
  • Country-led evaluation of expanded use of SPAQ in children from 6-10 years old  

  • Exploration of expanded duration of coverage in certain areas with a transmission period >4 months  
MMV Project Director
  • Dr André-Marie Tchouatieu